{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:01:33Z","timestamp":1791385293332,"version":"4.3.3"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.phrs.2024.107454","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T17:30:35Z","timestamp":1728667835000},"page":"107454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Efficacy of medications for the treatment of alcohol use disorder (AUD): A systematic review and meta-analysis considering baseline AUD severity"],"prefix":"10.1016","volume":"209","author":[{"given":"Roberta","family":"Agabio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Lopez-Pelayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Bruguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Sardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pecina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny M.","family":"Krupitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett M.","family":"Fitzmaurice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107454_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(22)00847-9","article-title":"Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020","volume":"400","author":"GBD 2020","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41591-023-02383-8","article-title":"Alcohol consumption and risks of more than 200 diseases in Chinese men","volume":"29","author":"Im","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2024.107454_bib4","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1747-597X-4-20","article-title":"The economic impact of alcohol consumption: a systematic review","volume":"4","author":"Thavorncharoensap","year":"2009","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"key":"10.1016\/j.phrs.2024.107454_bib6","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/S0140-6736(18)32744-2","article-title":"Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study","volume":"393","author":"Manthey","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2022.4308","article-title":"Alcohol-related deaths during the COVID-19 pandemic","volume":"327","author":"White","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107454_bib8","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.phrs.2024.107454_bib9","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2022"},{"key":"10.1016\/j.phrs.2024.107454_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","article-title":"Alcohol-use disorders","volume":"373","author":"Schuckit MA","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib11","article-title":"Remission from alcohol use disorder among males in the lundby cohort during 1947-1997","volume":"4829389","author":"Mattisson","year":"2018","journal-title":"Psychiatry J."},{"key":"10.1016\/j.phrs.2024.107454_bib12","doi-asserted-by":"crossref","first-page":"02","DOI":"10.35946\/arcr.v40.3.02","article-title":"Epidemiology of recovery from alcohol use disorder","volume":"40","author":"Tucker","year":"2020","journal-title":"Alcohol. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0140-6736(22)02583-1","article-title":"Deaths from alcohol-related liver disease in the UK: an escalating tragedy","volume":"401","author":"Allison","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol use disorders","volume":"394","author":"Carvalho","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(17)31045-0","article-title":"Causes of death up to 10 years after admissions to hospitals for self-inflicted, drug-related or alcohol-related, or violent injury during adolescence: a retrospective, nationwide, cohort study","volume":"390","author":"Herbert","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41572-022-00406-1","article-title":"Hazardous drinking and alcohol use disorders","volume":"8","author":"MacKillop","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2024.107454_bib17","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(18)31772-0","article-title":"Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500\u2008000 men and women in China","volume":"393","author":"Millwood","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib18","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(09)61034-5","article-title":"Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths","volume":"373","author":"Zaridze","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib20","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/add.12231","article-title":"Alcohol use disorders and mortality: a systematic review and meta-analysis","volume":"108","author":"Roerecke","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib21","doi-asserted-by":"crossref","first-page":"e1181","DOI":"10.4088\/JCP.13r08379","article-title":"Reduction of alcohol consumption and subsequent mortality in alcohol use disorders: systematic review and meta-analyses","volume":"74","author":"Roerecke","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib22","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/add.15357","article-title":"Treatment rates for alcohol use disorders: a systematic review and meta-analysis","volume":"116","author":"Mekonen","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000362407","article-title":"Attitudes towards alcohol dependence and affected individuals: persistence of negative stereotypes and illness beliefs between 1990 and 2011","volume":"20","author":"Schomerus","year":"2014","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000531502","article-title":"Education and training in addiction medicine and psychology across Europe: a EUFAS survey","volume":"30","author":"Bramness","year":"2024","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000537799","article-title":"Education and training in alcohology in Italy","volume":"30","author":"Agabio","year":"2024","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib26","article-title":"Alcoholics Anonymous and other 12-step programs for alcohol use disorder","volume":"3","author":"Kelly","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2024.107454_bib27","article-title":"Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users","volume":"12","author":"Klimas","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl","key":"10.1016\/j.phrs.2024.107454_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.15288\/jsads.2014.s17.68","article-title":"Psychosocial approaches to alcohol use disorders since 1940: a review","volume":"75","author":"McCrady","year":"2014","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.phrs.2024.107454_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.08.004","article-title":"An initial meta-analysis of Acceptance and Commitment Therapy for treating substance use disorders","volume":"155","author":"Lee","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2024.107454_bib30","article-title":"Mindfulness-based interventions for substance use disorders","volume":"10","author":"Goldberg","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2024.107454_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1360-0443.2002.00019.x","article-title":"Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders","volume":"97","author":"Miller","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib32","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/acer.15118","article-title":"Medications for treating alcohol use disorder: a narrative review","volume":"47","author":"Kranzler","year":"2023","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/alcalc\/agad090","article-title":"Baclofen in the treatment of alcohol use disorder: tailored doses matter","volume":"59","author":"de Beaurepaire","year":"2024","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.phrs.2024.107454_bib34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107454_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ajp.20230488","article-title":"Overview of alcohol use disorder","volume":"180","author":"Kranzler","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib36","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107454_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087366","article-title":"efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.phrs.2024.107454_bib38","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib39","article-title":"Baclofen for alcohol use disorder","volume":"1","author":"Agabio","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2024.107454_bib40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/02698811221149643","article-title":"A Bayesian meta-analysis of topiramate's effectiveness for individuals with alcohol use disorder","volume":"37","author":"Fluyau","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20054091","article-title":"Efficacy of varenicline in the treatment of alcohol dependence: an updated meta-analysis and meta-regression","volume":"20","author":"Phimarn","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.phrs.2024.107454_bib43","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib44","first-page":"e277","article-title":"First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario","volume":"63","author":"Spithoff","year":"2017","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.phrs.2024.107454_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.drugalcdep.2016.06.027","article-title":"National trends in alcohol pharmacotherapy: findings from an Australian claims database","volume":"166","author":"Morley","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2024.107454_bib46","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41386-021-01097-0","article-title":"Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study","volume":"46","author":"Biernacka","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2024.107454_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000433579","article-title":"Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review","volume":"22","author":"Agabio","year":"2016","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40429-023-00535-x","article-title":"Pharmacological treatments for alcohol use disorder: considering the role of sex and gender","volume":"11","author":"Kirsch","year":"2024","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.phrs.2024.107454_bib49","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/acer.12197","article-title":"The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies","volume":"37","author":"Litten","year":"2013","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S2215-0366(14)00092-3","article-title":"Placebo effects in psychiatry: mediators and moderators","volume":"2","author":"Weimer","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/JCP.0b013e3182983e73","article-title":"Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time","volume":"33","author":"Del Re","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib52","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/acer.14670","article-title":"Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: a meta-regression analysis to develop an enrichment strategy","volume":"45","author":"Scherrer","year":"2021","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib53","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/acer.14674","article-title":"Alcohol use disorder severity moderates clinical response to varenicline","volume":"45","author":"Donato","year":"2021","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fpsyt.2013.00075","article-title":"Modeling alcohol use disorder severity: an integrative structural equation modeling approach","volume":"4","author":"Moallem","year":"2013","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/B978-0-444-62619-6.00033-1","article-title":"psychiatric disorders and alcoholism","volume":"125","author":"Rich Stephen","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.phrs.2024.107454_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2024.107454_bib57","article-title":"Medications for alcohol use disorder: a systematic review and meta-analysis of clinical trials identified in literature and clinical trial registers","author":"Agabio","year":"2022","journal-title":"Prospero"},{"key":"10.1016\/j.phrs.2024.107454_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40290-024-00526-x","article-title":"Endpoints for pharmacotherapy trials for alcohol use disorder","volume":"38","author":"Belnap","year":"2024","journal-title":"Pharm. Med."},{"key":"10.1016\/j.phrs.2024.107454_bib59","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/add.13341","article-title":"Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries","volume":"111","author":"Kalinowski","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib60","first-page":"144","article-title":"Defining risk drinking","volume":"34","author":"Dawson","year":"2011","journal-title":"Alcohol. Res. Health"},{"key":"10.1016\/j.phrs.2024.107454_bib61","unstructured":"J. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (2011)."},{"key":"10.1016\/j.phrs.2024.107454_bib62","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2024.107454_bib63","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.phrs.2024.107454_bib64","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","article-title":"Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial","volume":"156","author":"Anton","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib65","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.jcp.0000172071.81258.04","article-title":"Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence","volume":"25","author":"Anton","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib66","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107454_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","article-title":"A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence","volume":"28","author":"Anton","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.phrs.2024.107454_bib69","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14367","article-title":"A double-blind randomized controlled trial of doxazosin for co-occurring PTSD and alcohol use disorder in veterans","volume":"84","author":"Back","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib70","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","article-title":"A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence","volume":"27","author":"Balldin","year":"2003","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0376-8716(02)00105-9","article-title":"The use of divalproex in alcohol relapse prevention: a pilot study","volume":"67","author":"Brady","year":"2002","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2024.107454_bib72","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4088\/JCP.v69n0502","article-title":"A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders","volume":"69","author":"Brown","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2215-0366(20)30489-2","article-title":"Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial","volume":"8","author":"Collins","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib74","first-page":"297","article-title":"Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics","volume":"31","author":"Cornelius","year":"1995","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.phrs.2024.107454_bib75","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/acer.12854","article-title":"Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial","volume":"39","author":"de Bejczy","year":"2015","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib76","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1530-0277.1991.tb05197.x","article-title":"Bromocriptine in the treatment of alcohol dependence","volume":"15","author":"Dongier","year":"1991","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety","volume":"43","author":"Falk","year":"2019","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib78","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1530-0277.2000.tb02038.x","article-title":"Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone","volume":"24","author":"Fawcett","year":"2000","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib79","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1530-0277.2011.01716.x","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients","volume":"36","author":"Fertig","year":"2012","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib80","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2013.8268","article-title":"Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial","volume":"310","author":"Foa","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107454_bib81","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1530-0277.1992.tb00658.x","article-title":"Gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study","volume":"16","author":"Gallimberti","year":"1992","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib82","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib83","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41386-021-01055-w","article-title":"Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial","volume":"46","author":"Garbutt","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2024.107454_bib84","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.alcohol.2007.03.011","article-title":"Bupropion and nicotine patch as smoking cessation aids in alcoholics","volume":"41","author":"Grant","year":"2007","journal-title":"Alcohol"},{"key":"10.1016\/j.phrs.2024.107454_bib85","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib86","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1530-0277.2002.tb02682.x","article-title":"A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial","volume":"26","author":"Guardia","year":"2002","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib87","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.ALC.0000125352.06688.F7","article-title":"A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder","volume":"28","author":"Guardia","year":"2004","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2021.06.003","article-title":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study","volume":"52","author":"Guiraud","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib89","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib90","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ALC.0000118313.63897.EE","article-title":"Nefazodone treatment of comorbid alcohol dependence and major depression","volume":"28","author":"Hernandez-Avila","year":"2004","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s002130050688","article-title":"Naltrexone treatment of comorbid alcohol and cocaine use disorders","volume":"139","author":"Hersh","year":"1998","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.phrs.2024.107454_bib92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2017.11.017","article-title":"Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: a randomized controlled trial","volume":"184","author":"Hurt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2024.107454_bib93","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107454_bib94","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/adb.12275","article-title":"Role of the \u03b11 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial","volume":"21","author":"Kenna","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.phrs.2024.107454_bib95","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.ALC.0000145688.30448.2C","article-title":"Effectiveness of naltrexone in a community treatment program","volume":"28","author":"Killeen","year":"2004","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib96","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archpsyc.1994.03950090052008","article-title":"Buspirone treatment of anxious alcoholics. A placebo-controlled trial","volume":"51","author":"Kranzler","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib97","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.152.3.391","article-title":"Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics","volume":"152","author":"Kranzler","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib98","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","article-title":"Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial","volume":"22","author":"Kranzler","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2024.107454_bib99","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","article-title":"Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial","volume":"28","author":"Kranzler","year":"2004","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib100","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence","volume":"345","author":"Krystal","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107454_bib101","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-014-3652-9","article-title":"A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers","volume":"232","author":"Leggio","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.phrs.2024.107454_bib102","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.drugalcdep.2013.06.032","article-title":"Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial","volume":"133","author":"Likhitsathian","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2024.107454_bib103","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","article-title":"A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients","volume":"36","author":"Litten","year":"2012","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib104","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1530-0277.1996.tb01644.x","article-title":"Buspirone in the treatment of alcohol dependence: a placebo-controlled trial","volume":"20","author":"Malec","year":"1996","journal-title":"Alcohol Clin. Exp. Res"},{"key":"10.1016\/j.phrs.2024.107454_bib105","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib106","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib107","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archpsyc.1996.01830030054009","article-title":"Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial","volume":"53","author":"McGrath","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib108","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/alcalc\/agaa133","article-title":"Efficacy of self-administered intranasal oxytocin on alcohol use and craving after detoxification in patients with alcohol dependence. a double-blind placebo-controlled trial","volume":"56","author":"Melby","year":"2021","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.phrs.2024.107454_bib109","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/pcn.12914","article-title":"Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial","volume":"73","author":"Miyata","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2024.107454_bib110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.jcp.0000095346.32154.41","article-title":"Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial","volume":"23","author":"Moak","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib111","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1360-0443.2006.01555.x","article-title":"Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial","volume":"101","author":"Morley","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib112","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","article-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","volume":"49","author":"Morley","year":"2014","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.phrs.2024.107454_bib113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1530-0277.1997.tb03733.x","article-title":"A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence","volume":"21","author":"Mueller","year":"1997","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib115","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","article-title":"High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial","volume":"25","author":"M\u00fcller","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib116","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/alcalc\/agg038","article-title":"Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study","volume":"38","author":"Namkoong","year":"2003","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.phrs.2024.107454_bib117","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1360-0443.1995.tb01013.x","article-title":"Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems","volume":"90","author":"Naranjo","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib118","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1530-0277.2008.00682.x","article-title":"Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial","volume":"32","author":"O'Malley","year":"2008","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib119","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1530-0277.2008.00698.x","article-title":"A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention","volume":"32","author":"Oslin","year":"2008","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108149","article-title":"A randomized pilot trial of topiramate for alcohol use disorder in veterans with traumatic brain injury: effects on alcohol use, cognition, and post-concussive symptoms","volume":"214","author":"Pennington","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2024.107454_bib121","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-003-1658-9","article-title":"Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia","volume":"172","author":"Petrakis","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.phrs.2024.107454_bib122","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders","volume":"57","author":"Petrakis","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/add.13943","article-title":"Mecamylamine treatment for alcohol dependence: a randomized controlled trial","volume":"113","author":"Petrakis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004714-200104000-00005","article-title":"Double-blind clinical trial of sertraline treatment for alcohol dependence","volume":"21","author":"Pettinati","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib125","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jsat.2007.05.011","article-title":"Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence","volume":"34","author":"Pettinati","year":"2008","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.phrs.2024.107454_bib126","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1521-0391.2014.12146.x","article-title":"A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence","volume":"23","author":"Pettinati","year":"2014","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.phrs.2024.107454_bib127","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0000000000001056","article-title":"Efficacy of varenicline in patients with severe alcohol dependence: a pilot double-blind randomized and controlled study","volume":"39","author":"Pfeifer","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","article-title":"Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up","volume":"52","author":"Ponizovsky","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.phrs.2024.107454_bib129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/15504263.2011.569440","article-title":"Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence","volume":"7","author":"Ralevski","year":"2011","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.phrs.2024.107454_bib130","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/JCP.0b013e3181bfdb79","article-title":"Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence","volume":"29","author":"Rubio","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107454_bib131","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/10550490490480982","article-title":"Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy","volume":"13","author":"Schmitz","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.phrs.2024.107454_bib132","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/15504263.2018.1549764","article-title":"A pilot randomized, placebo-controlled trial of glycine for treatment of schizophrenia and alcohol dependence","volume":"15","author":"Serrita","year":"2019","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.phrs.2024.107454_bib133","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1192\/bjp.150.2.164","article-title":"Tiapride in the long-term management of alcoholics of anxious or depressive temperament","volume":"150","author":"Shaw","year":"1987","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib134","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","article-title":"A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence","volume":"33","author":"Simpson","year":"2009","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib135","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/acer.12703","article-title":"A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder","volume":"39","author":"Simpson","year":"2015","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib136","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1176\/appi.ajp.2018.17080913","article-title":"Double-blind randomized clinical trial of prazosin for alcohol use disorder","volume":"175","author":"Simpson TL","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib137","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1399-5618.2011.00973.x","article-title":"A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report","volume":"14","author":"Tolliver","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2024.107454_bib138","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/10550490902787007","article-title":"A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling","volume":"18","author":"Toneatto","year":"2009","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.phrs.2024.107454_bib139","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","article-title":"Naltrexone and alcohol dependence. Role of subject compliance","volume":"54","author":"Volpicelli","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib140","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.4088\/JCP.v65n1017","article-title":"Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study","volume":"65","author":"Wetzel","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib141","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ADM.0000000000000413","article-title":"A randomized, placebo-controlled, clinical trial of prazosin for the treatment of alcohol use disorder","volume":"12","author":"Wilcox","year":"2018","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.phrs.2024.107454_bib142","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1523\/JNEUROSCI.19-01-00484.1999","article-title":"Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems","volume":"19","author":"Amanzio","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2024.107454_bib143","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1523\/JNEUROSCI.0439-05.2005","article-title":"Placebo effects mediated by endogenous opioid activity on mu-opioid receptors","volume":"25","author":"Zubieta","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2024.107454_bib144","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/mp.2014.164","article-title":"Molecular mechanisms of placebo responses in humans","volume":"20","author":"Peci\u00f1a","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107454_bib145","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.1067176","article-title":"Placebo and opioid analgesia-- imaging a shared neuronal network","volume":"295","author":"Petrovic","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107454_bib146","doi-asserted-by":"crossref","first-page":"11056","DOI":"10.1073\/pnas.0702413104","article-title":"Placebo effects on human mu-opioid activity during pain","volume":"104","author":"Wager","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107454_bib147","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1060937","article-title":"Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease","volume":"293","author":"de la Fuente-Fern\u00e1ndez","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107454_bib148","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neuron.2007.06.028","article-title":"Individual differences in reward responding explain placebo-induced expectations and effects","volume":"55","author":"Scott","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2024.107454_bib149","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0140-6736(78)92762-9","article-title":"The mechanism of placebo analgesia","volume":"2","author":"Levine","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107454_bib150","first-page":"1002","article-title":"\u03bc opioid antagonist naltrexone partially abolishes the antidepressant placebo effect and reduces orbitofrontal cortex encoding of reinforcement","volume":"6","author":"Peci\u00f1a","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.phrs.2024.107454_bib151","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/oxfordjournals.alcalc.a008221","article-title":"Subtypes of alcoholism and their role in therapy","volume":"31","author":"Lesch","year":"1996","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.phrs.2024.107454_bib152","series-title":"NeuroPsychopharmacotherapy","article-title":"Therapy of Withdrawal Syndromes, Addiction Disorders, and Substitution Therapies","author":"Lesch","year":"2022"},{"key":"10.1016\/j.phrs.2024.107454_bib153","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11065-008-9080-z","article-title":"Typologies of alcohol dependence. From Jellinek to genetics and beyond","volume":"19","author":"Leggio","year":"2009","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.phrs.2024.107454_bib154","first-page":"00240","article-title":"Low-dose ondansetron: a candidate prospective precision medicine to treat alcohol use disorder endophenotypes","volume":"S0953-6205","author":"Johnson","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.phrs.2024.107454_bib155","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/17425255.2019.1628218","article-title":"Pharmacogenetics of alcohol use disorder treatmentsan update","volume":"15","author":"Hartwell","year":"2019","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.phrs.2024.107454_bib156","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2217\/pgs-2020-0079","article-title":"Pharmacotherapies and personalized medicine for alcohol use disorder: a review","volume":"21","author":"Lohoff","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2024.107454_bib157","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/ADM.0000000000000992","article-title":"Pharmacotherapies for adults with alcohol use disorders: a systematic review and network meta-analysis","volume":"16","author":"Bahji","year":"2022","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.phrs.2024.107454_bib158","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2024.107454_bib159","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107454_bib160","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.phrs.2024.107454_bib161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.2751","article-title":"Gabapentinoids for treatment of alcohol use disorder: a systematic review and meta-analysis","volume":"35","author":"Cheng","year":"2020","journal-title":"Hum. Psychopharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:57:10Z","timestamp":1731009430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824003992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":161,"alternative-id":["S1043661824003992"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107454","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of medications for the treatment of alcohol use disorder (AUD): A systematic review and meta-analysis considering baseline AUD severity","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107454"}}